ClinicalTrials.gg
CompletedNCT00971867Updated Apr 8, 2022Results posted

Rollover Study of Weekly Paclitaxel (BMS-181339) in Patients With Head and Neck Cancer

A Phase 2 interventional study of Paclitaxel in Head and Neck Cancer, sponsored by Bristol-Myers Squibb. Completed at 9 sites in Japan. Per ClinicalTrials.gov, last updated 2022-04-08.

Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 3 years after the study started (first participant enrolled Aug 2006, registered Sep 2009).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
11
Allocation
Not applicable
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 61 studies testing paclitaxel in Head and Neck Neoplasms — 8 open to participants now, 11 under way, none of them phase 3. Paclitaxel · Head and Neck Neoplasms.

Enrollment
51st of 55
11 · median 40
Started
2006
with 2 others
Phase 2
43 of 61
8 open now
Registered
36th of 61
by date
Lead sponsor
4 of 61
Bristol-Myers Squibb

Among the 61 studies testing paclitaxel in Head and Neck Neoplasms, this one is the 51st largest by enrollment of the 55 interventional ones that give a count, is one of 3 that started in 2006, is one of 43 in phase 2, and was the 36th registered.

Head and Neck Neoplasms

2,714 studies on the registry are indexed under Head and Neck Neoplasms; 597 are open to participants now.

Browse Head and Neck Neoplasms studies →

Open to participants now

8 of the 61 studies testing paclitaxel in Head and Neck Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About paclitaxel

Paclitaxel: first FDA approval 1992 (TAXOL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 456 Head and Neck Neoplasms studies recruiting now, 348 (76%) set no upper age limit and 51 (11%) stop at 75 or younger; 22 take children under 18; 27 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 61 studies testing paclitaxel in Head and Neck Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to provide access to paclitaxel therapy to subjects with advanced head and neck cancer who have completed the previous late phase 2 study (CA139-388) and should have continued therapy with paclitaxel as the discretion of the investigator, and to evaluate the frequency and the severity of observed adverse reactions in treated subjects

03

Conditions studied

  • Head and Neck Cancer
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • Subjects with advanced head and neck cancer who have completed the previous late phase 2 study (CA139-388) and should have continued therapy with paclitaxel as the discretion of the investigator
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    Paclitaxel

    Drug: Paclitaxel

Interventions

  • Solution, I.V., 100 mg/m2 Weekly for 6 of 7 weeks, Until disease progression or unacceptable toxicity became apparent

    Also known as: Taxol, BMS-181339

06

What researchers measure

Primary outcomes

  1. Number of Participants With SAEs

    Number of Participants with SAEs

    Time frame: From the first infusion to the completion of study. Approximately up to 28 months

  2. Number of Participants With Adverse Events Leading to Discontinuation

    Number of Participants with Adverse Events Leading to Discontinuation

    Time frame: From the first infusion to the completion of study. Approximately up to 28 months

  3. Number of Participants With Adverse Events

    Number of Participants with Adverse Events

    Time frame: From the first infusion to the completion of study. Approximately up to 28 months

  4. Number of Participants With Laboratory Abnormalities

    Number of Participants with Laboratory Abnormalities

    Time frame: From the first infusion to the completion of study. Approximately up to 28 months

  5. Number of Participants With Drug Related Laboratory Abnormalities

    Number of Participants with Drug Related Laboratory Abnormalities

    Time frame: From the first infusion to the completion of study. Approximately up to 28 months

Secondary outcomes

  1. Number of Participants With Best Overall Response Per RECIST Criteria

    Best overall response is represented by the number participants who have had complete response, partial response and have stable disease.

    Time frame: From the enrollment in CA139-388 (NCT00855764) study up to 904 days after the first infusion in CA139-388 study. Approximately up to 42 Months

  2. Number of Participants With Best Overall Response Per the General Rules for Clinical and Pathological Studies of Head and Neck Cancer

    Best overall response is represented by the number participants who have had complete response, partial response and not completed.

    Time frame: From the enrollment in CA139-388 (NCT00855764) study up to 904 days after the first infusion in CA139-388 study. Approximately up to 42 Months

  3. Duration of Overall Response as Per RECIST Criteria

    DOR is defined as the median time from the first date of Partial Response to the first date of Progressive Disease. Participants were evaluated for DOR in a separate study (NCT00971867).

    Time frame: From the enrollment in CA139-388 (NCT00855764) study up to 904 days after the first infusion in CA139-388 study. Approximately up to 42 Months

  4. Duration of Overall Response as Per the General Rules for Clinical and Pathological Studies of Head and Neck Cancer

    Best overall response is represented by the number participants who have had complete response, partial response and not completed.

    Time frame: From the enrollment in CA139-388 (NCT00855764) study up to 904 days after the first infusion in CA139-388 study. Approximately up to 42 Months

07

Results

Posted Apr 8, 2022

Participant flow

Participant flow — Overall Study
MilestonePaclitaxel
Started11
Completed0
Not completed11
Withdrew: Adverse event4
Withdrew: Participant withdrew consent1
Withdrew: Disease progression6

Outcome measures

PrimaryNumber of Participants With SAEs

Number of Participants with SAEs

Time frame:
From the first infusion to the completion of study. Approximately up to 28 months
Reported as:
Number · Number of Participants
Number of Participants With SAEs
Number of ParticipantsPaclitaxel
Number of Participants With SAEs3
PrimaryNumber of Participants With Adverse Events Leading to Discontinuation

Number of Participants with Adverse Events Leading to Discontinuation

Time frame:
From the first infusion to the completion of study. Approximately up to 28 months
Reported as:
Number · Number of Participants
Number of Participants With Adverse Events Leading to Discontinuation
Number of ParticipantsPaclitaxel
Number of Participants With Adverse Events Leading to Discontinuation5
PrimaryNumber of Participants With Adverse Events

Number of Participants with Adverse Events

Time frame:
From the first infusion to the completion of study. Approximately up to 28 months
Reported as:
Number · Number of Participants
Number of Participants With Adverse Events
Number of ParticipantsPaclitaxel
Number of Participants With Adverse Events11
PrimaryNumber of Participants With Laboratory Abnormalities

Number of Participants with Laboratory Abnormalities

Time frame:
From the first infusion to the completion of study. Approximately up to 28 months
Reported as:
Number · Number of Participants
Number of Participants With Laboratory Abnormalities
Number of ParticipantsPaclitaxel
Number of Participants With Laboratory Abnormalities11
PrimaryNumber of Participants With Drug Related Laboratory Abnormalities

Number of Participants with Drug Related Laboratory Abnormalities

Time frame:
From the first infusion to the completion of study. Approximately up to 28 months
Reported as:
Number · Number of Participants
Number of Participants With Drug Related Laboratory Abnormalities
Number of ParticipantsPaclitaxel
Number of Participants With Drug Related Laboratory Abnormalities11
SecondaryNumber of Participants With Best Overall Response Per RECIST Criteria

Best overall response is represented by the number participants who have had complete response, partial response and have stable disease.

Time frame:
From the enrollment in CA139-388 (NCT00855764) study up to 904 days after the first infusion in CA139-388 study. Approximately up to 42 Months
Reported as:
Number · Number of Participants
Number of Participants With Best Overall Response Per RECIST Criteria
Number of ParticipantsPaclitaxel
Complete Response (CR)1
Partial Response (PR)6
Stable Disease (SD)4
SecondaryNumber of Participants With Best Overall Response Per the General Rules for Clinical and Pathological Studies of Head and Neck Cancer

Best overall response is represented by the number participants who have had complete response, partial response and not completed.

Time frame:
From the enrollment in CA139-388 (NCT00855764) study up to 904 days after the first infusion in CA139-388 study. Approximately up to 42 Months
Reported as:
Number · Number of Participants
Number of Participants With Best Overall Response Per the General Rules for Clinical and Pathological Studies of Head and Neck Cancer
Number of ParticipantsPaclitaxel
Complete Response (CR)1
Partial Response (PR)9
Not Completed1
SecondaryDuration of Overall Response as Per RECIST Criteria

DOR is defined as the median time from the first date of Partial Response to the first date of Progressive Disease. Participants were evaluated for DOR in a separate study (NCT00971867).

Time frame:
From the enrollment in CA139-388 (NCT00855764) study up to 904 days after the first infusion in CA139-388 study. Approximately up to 42 Months
Reported as:
Median · Days
Duration of Overall Response as Per RECIST Criteria
DaysPaclitaxel
Duration of Overall Response as Per RECIST Criteria222 (70 to 847)
SecondaryDuration of Overall Response as Per the General Rules for Clinical and Pathological Studies of Head and Neck Cancer

Best overall response is represented by the number participants who have had complete response, partial response and not completed.

Time frame:
From the enrollment in CA139-388 (NCT00855764) study up to 904 days after the first infusion in CA139-388 study. Approximately up to 42 Months
Reported as:
Median · Days
Duration of Overall Response as Per the General Rules for Clinical and Pathological Studies of Head and Neck Cancer
DaysPaclitaxel
Duration of Overall Response as Per the General Rules for Clinical and Pathological Studies of Head and Neck Cancer269 (140 to 904)

Adverse events

Collected over From the first infusion to the completion of study. Approximately up to 28 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Paclitaxel0/11 (0%)3/11 (27.3%)11/11 (100%)
Most frequent serious events
Most frequent serious events
EventPaclitaxel
Interstitial Lung DiseaseRespiratory, thoracic and mediastinal disorders1/11
VomittingGastrointestinal disorders1/11
DyspneaRespiratory, thoracic and mediastinal disorders1/11
Cancer PainGeneral disorders1/11
Most frequent other events
Most frequent other events
EventPaclitaxel
AlopeciaSkin and subcutaneous tissue disorders11/11
HypoesthesiaNervous system disorders9/11
FatigueGeneral disorders7/11
Weight DisorderGeneral disorders5/11
Nail DisorderGeneral disorders5/11

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Paclitaxel
<=18 years0
Between 18 and 65 years7
>=65 years4
Sex: Female, Male
Sex: Female, Male(Participants)Paclitaxel
Female2
Male9
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Paclitaxel
Hispanic or Latino0
Not Hispanic or Latino0
Unknown or Not Reported11
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Paclitaxel
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported11
08

Study locations

9 sites
  • Local Institution
    Kashiwa-shi, Chiba 2778577, Japan
  • Local Institution
    Matsuyama-shi, Ehime, Japan
  • Local Institution
    Kagoshima-shi, Kagoshima 8900075, Japan
  • Local Institution
    Yokohama, Kanagawa 241-0815, Japan
  • Local Institution
    Osaka-shi, Osaka 5458586, Japan
  • Local Institution
    Sunto-gun, Shizuoka 4118777, Japan
  • Local Institution
    Meguro-ku, Tokyo 1520021, Japan
  • Local Institution
    Kanagawa, Japan
  • Local Institution
    Tochigi, 329-0498, Japan
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2006 to primary completion in Nov 2008, 27 months.

Results were first posted in Apr 2022, 13 years 4 months after primary completion.

Of 44 industry-sponsored phase 2 interventional studies under Head and Neck Neoplasms, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 27 months is below that.

Counting every sponsor, half of 260 studies reached it within 51 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 3, 2009
First posted
Sep 4, 2009
StartActual
Aug 4, 2006
Primary completionActual
Nov 26, 2008
CompletionActual
Nov 26, 2008
Results first posted
Apr 8, 2022
Last update
Apr 8, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00971867
Responsible party
Sponsor
First posted
Sep 4, 2009
Start date
Aug 4, 2006
Primary completion
Nov 26, 2008
Completion
Nov 26, 2008
Results posted
Apr 8, 2022
Last update
Apr 8, 2022

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Paclitaxel

Start the discussion